Egypt
· Delayed Price · Currency is EGP MCRO Statistics
Total Valuation
Macro Group Pharmaceuticals (Macro Capital) S.A.E has a market cap or net worth of EGP 1.02 billion. The enterprise value is 1.20 billion.
| Market Cap | 1.02B |
| Enterprise Value | 1.20B |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Macro Group Pharmaceuticals (Macro Capital) S.A.E has 570.21 million shares outstanding. The number of shares has decreased by -0.89% in one year.
| Shares Outstanding | 570.21M |
| Shares Change (YoY) | -0.89% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 12.01% |
| Float | 241.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| PB Ratio | 37.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.07 |
| EV / Sales | 3.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.35 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 10.41.
| Current Ratio | 0.91 |
| Quick Ratio | 0.27 |
| Debt / Equity | 10.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.36 |
| Interest Coverage | -8.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -25.22% |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 2.38 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 1,752,395 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Macro Group Pharmaceuticals (Macro Capital) S.A.E had revenue of EGP 344.02 million and -390.79 million in losses. Loss per share was -0.69.
| Revenue | 344.02M |
| Gross Profit | 151.46M |
| Operating Income | -316.94M |
| Pretax Income | -397.22M |
| Net Income | -390.79M |
| EBITDA | -314.91M |
| EBIT | -316.94M |
| Loss Per Share | -0.69 |
Balance Sheet
The company has 107.28 million in cash and 284.80 million in debt, giving a net cash position of -177.52 million or -0.31 per share.
| Cash & Cash Equivalents | 107.28M |
| Total Debt | 284.80M |
| Net Cash | -177.52M |
| Net Cash Per Share | -0.31 |
| Equity (Book Value) | 27.35M |
| Book Value Per Share | 0.05 |
| Working Capital | -41.93M |
Cash Flow
In the last 12 months, operating cash flow was -62.11 million and capital expenditures -3.18 million, giving a free cash flow of -65.29 million.
| Operating Cash Flow | -62.11M |
| Capital Expenditures | -3.18M |
| Free Cash Flow | -65.29M |
| FCF Per Share | -0.11 |
Margins
Gross margin is 44.03%, with operating and profit margins of -92.13% and -113.59%.
| Gross Margin | 44.03% |
| Operating Margin | -92.13% |
| Pretax Margin | -115.46% |
| Profit Margin | -113.59% |
| EBITDA Margin | -91.54% |
| EBIT Margin | -92.13% |
| FCF Margin | -18.98% |
Dividends & Yields
Macro Group Pharmaceuticals (Macro Capital) S.A.E does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.89% |
| Shareholder Yield | 0.89% |
| Earnings Yield | -38.71% |
| FCF Yield | -6.40% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Macro Group Pharmaceuticals (Macro Capital) S.A.E has an Altman Z-Score of 0.15. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.15 |
| Piotroski F-Score | n/a |